Altre lingue Compugen Ltd.

Azioni

CGEN

IL0010852080

Mercato chiuso - Nasdaq Altri mercati azionari 19:00:00 03/07/2024			Variaz. 5gg	Var. 1 gen.
1,67 ^USD	-1,18%		-5,11%	-15,66%

27/06	Transcript : Compugen Ltd. - Special Call
30/05	Compugen Ltd. riceverà un pagamento miliare da Astrazeneca in seguito al dosaggio del primo paziente nel secondo studio di Fase 3 che valuta Rilvegostomig	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Compugen to Present at Upcoming Antibody Industrial Symposium	17/06
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	30/05
Compugen Ltd. to Receive Milestone Payment from Astrazeneca Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig	30/05
Compugen : Reports First Quarter 2024 Results	20/05
Earnings Flash (CGEN) COMPUGEN Reports Q1 Revenue $2.6M, vs. Street Est of $1.2M	20/05
Compugen: Q1 Earnings Snapshot	20/05
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	20/05
Compugen Reports First Quarter 2024 Results	20/05
Compugen : Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential	16/05
Compugen Names David Silberman CFO	15/05
Compugen Appoints David Silberman as Chief Financial Officer	15/05
Compugen Ltd. Announces CFO Changes, Effective August 15, 2024	15/05
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024	06/05
Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	26/04
Compugen : To Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024	25/04
Compugen to Participate in Two Upcoming Investor Conferences	03/04
Compugen : Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	11/03
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy	11/03
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	07/03
Compugen : To Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024	06/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Compugen Ltd.

Azioni

CGEN

IL0010852080

Altre lingue

Filtri